Molecular Cancer Therapeutics Impact Factor, Indexing, Ranking 2024

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody-drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.Specific areas of interest are the disclosure of translational investigations of novel drug therapies, preclinical studies of approved therapeutics (including their combination with radiation therapy), mechanisms of action, mitigation of resistance, biomarkers of response, novel models and technology, and applications of big data in drug discovery.The following guidelines, which may be revised from time to time, describe what the Editors are looking for in submitted manuscripts: Data/experiments are substantive and support conclusions; all key experiments are designed and performed properly. Sufficient detail is provided to facilitate repetition of the experiments to verify data. Rigorous statistical evaluation is performed. Sufficient group size is used for animal studies. Appropriate replicates in cellular studies are used. Relevant cell lines, animal models, and assays are utilized. Studies must be performed according to AACR and Institutional Guidelines. Multiple relevant cell lines (or patient specimens) are examined/used/studied to support conclusions. Studies are performed using relevant concentrations of agents, conditions, schedules, and other related material. Where human data exists, the data should be used to define parameters for laboratory studies. Appropriate controls are employed for all experiments (especially inactive analog compounds). In vivo studies should go beyond establishment of biological effect and show modulation of the intended target (or cellular pathway) in vivo. Pharmacokinetic (PK)/pharmacodynamics (PD) studies are extremely useful; dose-response should be demonstrated. Inclusion of relevant structures of compounds mentioned or used in the work is essential and enhances the readability of the paper. Studies with uncharacterized mixture of Natural Products will not be considered. For novel structures previously unreported, experimental details of synthesis should be included in the main body of the paper or in Supplementary Material. Any references or patents cited that provide the synthesis of compounds should be specific, not general, and should be easily obtained.

《分子癌症治疗学》杂志专注于肿瘤学治疗剂的发现和临床前开发的研究转化。为了反映治疗学领域的不断演变，该杂志的兴趣范围涵盖所有选择性药物，包括小分子抑制剂、抗体-药物偶联物、抗体-细胞因子融合、双特异性抗体、细胞治疗、基因治疗、放射免疫治疗、疫苗、病毒治疗以及其他肿瘤学中的实验方法。特别关注的新药疗法转化研究、批准疗法的临床前研究（包括其与放射治疗的联合应用）、作用机制、耐药性缓解、反应生物标志物、新型模型和技术、大数据在药物发现中的应用等领域。以下指南（可能随时修订）概述了编辑在审稿时寻求的内容：数据/实验具有实质性和支持结论的能力；所有关键实验均设计合理、执行得当。提供充分细节，以促进实验重复验证数据。进行严格的统计分析。动物研究中使用足够的样本量。细胞研究中使用适当的重复次数。利用相关的细胞系、动物模型和检测方法。研究必须按照美国癌症研究协会（AACR）和机构指南进行。通过检查/使用/研究多个相关细胞系（或患者样本）来支持结论。使用相关浓度的试剂、条件、时间表和其他相关材料进行研究。存在人类数据时，应使用这些数据来定义实验室研究的参数。所有实验（尤其是非活性类似物）均采用适当的对照。体内研究应超越生物效应的建立，并显示在体内对目标（或细胞通路）的调节。药代动力学（PK）/药效学（PD）研究极为有用；应展示剂量-反应关系。提到或使用的工作中相关化合物的结构必须包含在内，并增强论文的可读性。未经表征的天然产物混合物研究将不予考虑。对于先前未报道的新结构，合成实验的详细情况应包括在论文主体或补充材料中。引用或提到的提供化合物合成的参考或专利应具体，而非泛泛而谈，并且易于获取。